Video_2_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_4_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_1_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Genetic correlations in viral load between single and coinfections of CrPV and DCV. by Ryan M. Imrie (15810854)

Subjects:

Interspecific correlations in viral load between single and coinfections of CrPV and DCV. by Ryan M. Imrie (15810854)

Subjects:

Viral loads of CrPV and DCV across host species during single and coinfection. by Ryan M. Imrie (15810854)

Subjects:

Viral loads of CrPV and DCV across DGRP lines during single and coinfection. by Ryan M. Imrie (15810854)

Subjects:

Transfection of inhibitors decrease their corresponding endogenous miRNAs and transfection of mimics increase corresponding miRNAs in SHSY5Y cells. by Yang-ja Lee (125845)

Endoscopic injection into the vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

Effect of 2%, 4%, and 6% HQ cream on behavioral activities. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) during 5minutes. …”

Effect of 2% HQ, 0.05% INN and 0.1% TAC on behavioral activities in C57BL/6 mice. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) of INN and TAC group during 5minutes, whereas no change in the number of grooming episodes (C). …”

AnxA5 results in a tendency to decrease the monocyte endothelium interaction in a flow model. by Robert Stöhr (3583700)

Loss of Rtr1 activity leads to decreased RNAPII occupancy at <i>SNR</i> genes and shortened <i>SNR</i> transcripts. by Jose F. Victorino (8595885)

AZT decreases basal and SMM-stimulated mRNA and protein expression levels of MUC5AC in human airway epithelia. by Carla Maria P. Ribeiro (263581)

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Large circles show mean of cells from 5 fields of view from a single animal. (D) Immunoblot showing p53 protein expression is decreased in colon tissue from 5-month old HA-MAD1 mice after 1 week of 6 mg/kg dox feed as compared to control. …”

VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”

HT1080 human sarcoma xenograft growth in CD-1 athymic mice and body weight comparison under therapy with intravenous (i.v.) tTF-NGR, tumor radiotherapy, and a combination of both t... by Caroline Brand (3448523)

“…<p>(A) Arrows show treatment intervention for tTF-NGR (1.5 mg/kg body weight (bw) x 5) or tumor radiotherapy (4.8 Gy x 2). …”

Genes showing 1.5 fold expression decrease in D381 relative to heterozygous <i>TOR1/tor1</i>. by Wanjun Qi (5571359)

Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”